This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - The article discusses Inhibrx Biosciences, Inc. (NASDAQ: INBX) and its recent developments, particularly following the sale of INBRX-101 to Sanofi [2]. Company Overview - Inhibrx Biosciences is highlighted for its continued advancement in the biotech sector, indicating a positive trajectory despite the sale of a key asset [2]. Investment Analysis - The author operates a service called Biotech Analysis Central, which provides in-depth analysis of various pharmaceutical companies, including a model portfolio of small and mid-cap stocks [2].